TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease ...

The oral molecular glue degrader aims to overcome resistance to standard ALK tyrosine kinase inhibitor therapies.

Is Zykadia Right for Me? Your health care provider will consider what type of lung cancer you have and whether it has spread to help choose the right treatment for you. Zykadia is used for NSCLC that ...

– ALINA data demonstrate Alecensa reduces disease recurrence in the early setting for people with ALK-positive non-small cell lung cancer (NSCLC), building on its long-established benefit in the ...

TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and ...

Quantifying clinical harm and financial waste from failure to deploy personalized medicine for patients with metastatic non-small cell lung cancer in the United States. This is an ASCO Meeting ...

About five percent of lung adenocarcinomas, one of the most common forms of lung cancer, are driven by a faulty fusion of two genes, EML4 and ALK. This fusion results in different variants, and until ...

AUSTIN, Texas, Oct. 14, 2025 /PRNewswire/ -- Genprex, Inc. (GNPX) ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for ...

Good morning, and welcome to Nuvalent's conference call. [Operator Instructions] Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to ...

VCU Massey is the first U.S. site in a global phase 2a trial for PTX-100, targeting cutaneous T-cell lymphoma. The BIPAVE-001 trial is evaluating AI-081, a PD-1 and VEGF bispecific antibody, for ...